Although the dominant importance of HER2 over other HER receptors is globally accepted [19], we were able to show a substantial impact of HER3 amplification on outcome of breast cancer disease (disease-free survival) even at low amplification rates. This evidence concerns the gene ERBB3 and breast carcinoma.